Protective Effect of Yidutiaogan Mixture on Hepatic Fibrosis Induced by Carbon Tetrachloride Complex Factors in Rats / 医药导报
Herald of Medicine
; (12): 1244-1249, 2017.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-658353
Biblioteca responsável:
WPRO
ABSTRACT
Objective To observe the effect of Yidutiaogan mixture on rat liver fibrosis induced by CCl4 complex factors. Methods Sixty SD rats were randomly divided into normal control group, model control group, colchicine group (0.2 mg·kg-1), Yidutiaogan mixture low-, medium-, and high-dose groups(2.7, 5.4, 10.8 mL·kg-1) (n=10).Except for normal control group, the other groups were given drinking water containing 10% ethanol, subcutaneous injection of 40%CCl4 in olive oil (3 mL·kg-1,twice weekly), and high-fat diet for 8 weeks as the model control group, and they were given relevant medicine intragastrically once a day during modeling. The rats were sacrificed, and the livers were harvested and stained with Masson staining to observe liver fibrosis. Serum levels of ALT, AST, ALP, ALB, HA, LN, PCⅢ, C-Ⅳ, and the levels of TIMP-1, MMP-1, MMP-2, MMP-13, and TGF-β1 in liver tissue were detected by biochemical assay, radioimmunoassay and ELISA. Results Compared with normal control group, serum levels of ALT, AST, ALP, HA, LN, PCⅢ, and C-Ⅳ were significantly increased in model control group, while serum level of ALB was significantly decreased (P<0.01); the levels of TIMP-1, MMP-2 and TGF-β1 in liver tissue were significantly increased, while the levels of MMP-1 and MMP-13 were significantly decreased (P<0.01).Compared with the model control group, serum levels of ALT, AST, HA, LN, PCⅢ, and C-Ⅳ as well as the levels of TIMP-1, MMP-2, and TGF-β1 in liver tissue were all significantly decreased in Yidutiaogan mixture medium-dose, high-dose, and colchicine groups( P<0.05);serum level of ALB as well as the levels of MMP-1 and MMP-13 in liver tissue were significantly increased(P<0.05).However, there was no statistical significance in above indexes in Yidutiaogan mixture low-dose group(P>0.05). Conclusion Yidutiaogan mixture could be used to prevent experimental hepatic fibrosis through regulating TIMPs/MMPs, suppressing TGF-β1 , reducing deposition of extracellular matrix in liver.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Herald of Medicine
Ano de publicação:
2017
Tipo de documento:
Artigo